Jeryl Hilleman

Jeri Hilleman was elected to the Novocure Board of Directors in July 2018. Ms. Hilleman is an experienced corporate director with close to 20 years of board experience building on her career as Chief Financial Officer of several international public life sciences companies including, Intersect ENT (acquired), Ocera Therapeutics (acquired), Amyris and Symyx Technologies (acquired). Ms. Hilleman is a Director and Chair of the Board of Omada Health (private) since July 2018 and a director of SI-Bone since December 2019. Ms. Hilleman also serves as a Federal Trade Commission monitor, including for the Amgen-Horizon merger. Ms. Hilleman is formerly a director of HilleVax, Cutera, Inc., Minerva Neurosciences and Talis Biomedical. 

Ms. Hilleman holds an A.B. from Brown University and an MBA from the Wharton Graduate School of Business. She is a member of the 1999 class of the Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.